Serum 2-methoxyestradiol, an estrogen metabolite, is positively associated with serum HDL-C in a population-based sample

Lipids

Volumn 47, Issue 1, 2012, Pages 35-38

  Masi, Christopher M ^a   Hawkley, Louise C ^a   Cacioppo, John T ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Atherosclerosis; Coronary artery disease; HDL; HMG CoA reductase; Lipoprotein metabolism; Mass spectrometry

Indexed keywords

2 METHOXYESTRADIOL; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; IN VITRO STUDY; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; MASS SPECTROMETRY; PROSPECTIVE STUDY;

ACYL COENZYME A; AFRICAN AMERICANS; BODY MASS INDEX; CHOLESTEROL, HDL; CHROMATOGRAPHY, LIQUID; ESTRADIOL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS; MASS SPECTROMETRY; MIDDLE AGED; POSTMENOPAUSE; TRIGLYCERIDES; UNITED STATES;

EQUIDAE;

EID: 84857042260     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-011-3600-y     Document Type: Article

References (31)

1. Ballantyne CM, Herd JA, Ferlic LL, Dunn K, Farmer JA et al (1999) Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 99:736-743 (Pubitemid 29083012)
2. Sanossian N, Tarlov NE (2008) HDL-C and LDL-C: their role in stroke pathogenesis and implications for treatment. Curr Treat Options Cardiovasc Med 10:195-206
3. Feig JE, Shamir R, Fisher EA (2008) Atheroprotective effects of HDL: beyond reverse cholesterol transport. Curr Drug Targets 9:196-203 (Pubitemid 351843600)
4. Nofer JR, Walter M, Assmann G (2005) Current understanding of the role of high-density lipoprotein in atherosclerosis and senescence. Expert Rev Cardiovasc Ther 3:1071-1086 (Pubitemid 41748374)
5. 3cholesterol and apolipoproteins A-1 and B in healthy men and women and associations with age, gender, hormonal status, and sex hormone use: The Stanford Five City Project. Prev Med 31:335-345
6. Bello N, Mosca L (2004) Epidemiology of coronary heart disease in women. Prog Cardiovasc Dis 46:287-295 (Pubitemid 38201291)
7. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC et al (2011) Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305:1305-1314
8. Krauss RM, Lindgren FT, Wingerd J, Bradley DD, Ramcharan S (1979) Effects of estrogens and progestins on high density lipoproteins. Lipids 14:113-118 (Pubitemid 9139166)
9. Lamon-Fava S, Micherone D (2004) Regulation of apoA-1 gene expression: mechanism of action of estrogen and genistein. J Lipid Res 45:106-112 (Pubitemid 38176620)
10. Walsh BW, Li H, Sacks FM (1994) Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res 35:2083-2093 (Pubitemid 24353080)
11. Bhavnani BR (2003) Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. J Steroid Biochem Mol Biol 85:473-482 (Pubitemid 37011124)
12. Lamon-Fava S, Postfai B, Diffenderfer M, DeLuca C, O'Connor J et al (2006) Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-1 kinetics in postmenopausal women. Arterioscler Thromb Vasc Biol 26:385-391 (Pubitemid 43732204)
13. Lopez D, Sanchez MD, Shea-Eaton W, McLean MP (2002) Estrogen activates the high-density lipoprotein receptor gene via binding to estrogen response elements and interaction with sterol regulatory element binding protein-1A. Endocrinology 143:2155-2168 (Pubitemid 34521562)
14. Jones DR, Schmidt RJ, Pickard RT, Foxworthy PS, Eacho PI (2002) Estrogen receptor-mediated repression of human hepatic lipase gene transcription. J Lipid Res 43:383-391 (Pubitemid 34252268)
15. Brinton EA, Eisenberg S, Breslow JL (1991) Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest 87:536-544
16. Staels B, Jansen H, van Tol A, Stahnke G, Will H et al (1990) Development, food intake, and ethinylestradiol influence hepatic triglyceride lipase and LDL-receptor mRNA levels in rats. J Lipid Res 31:1211-1218 (Pubitemid 20224718)
17. Acton S, Rigotti A, Landshulz KT, Xu S, Hobbs HH et al (1996) Identification of scavenger receptor SR-BI as a high-density lipoprotein receptor. Science 271:1518-1520
18. Jian B, de la Llera-Moya M, Ji Y, Wang N, Phillips MC et al (1998) Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors. J Biol Chem 271:518-520
19. Dubey RK, Tofovic SP, Jackson EK (2004) Cardiovascular pharmacology of estradiol metabolites. J Pharmacol Exp Ther 308:403-409 (Pubitemid 38134197)
20. Liu D, Bachman KA (1998) An investigation of the relationship between estrogen, estrogen metabolites and blood cholesterol levels in ovariectomized rats. J Pharmacol Exp Ther 286:561-568 (Pubitemid 28318034)
21. Tofovic S, Dubey RK, Jackson EK (2001) 2-Hydroxyestradiol attenuates the development of obesity, the metabolic syndrome, and vascular and renal dysfunction in obese ZSF1 rats. J Pharmacol Exp Ther 299:973-977 (Pubitemid 33104968)
22. Bourghart J, Bergstrom G, Krettek A, Sjoberg S, Boren J et al (2007) The endogenous estradiol metabolite 2-methoxyestradiol reduces atherosclerotic lesion formation in female apolipoprotein E-deficient mice. Endocrinology 9:4128-4132 (Pubitemid 47295675)
23. Barchiesi F, Lucchinetti E, Zaugg M, Ogunshola O, Wright M et al (2010) Candidate genes and mechanisms for 2-methoxyestradiol- mediated vasoprotection. Hypertension 56:964-972
24. Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA (1995) The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary artery disease: estimating the benefits of increasing HDL-C. JAMA 273:1032-1038
25. Zhu BT, Conney AH (1998) Functional role of estrogen metabolism in target cells: a review and perspectives. Carcinogenesis 19:1-27 (Pubitemid 28376821)
26. Xu X, Roman JM, Issaq HJ, Keefer LK, Veenstra TD et al (2007) Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry. Anal Chem 79:7813-7821 (Pubitemid 47622412)
27. Masi CM, Hawkley LC, Xu X, Veenstra TD, Cacioppo JT (2009) Serum estrogen metabolites and systolic blood pressure among middle-aged and older women and men. Am J Hypertens 22:1148-1153
28. Walsh BW, Spiegelman D, Morrissey M, Sacks FM (1999) Relationship between serum estradiol levels and the increases in high-density lipoprotein levels in postmenopausal women treated with oral estradiol. J Clin Endocriol Metab 84:985-989 (Pubitemid 29138230)
29. Semmens J, Rouse I, Beilin LJ, Masarei JRL (1983) Relationship of plasma HDL-cholesterol to testosterone, estradiol, and sexhormone-binding globulin levels in men and women. Metabolism 32:428-432 (Pubitemid 13083645)
30. Mueck AO, Seeger H, Lippert TH (2002) Estradiol metabolism and malignant disease. Maturitas 43:1-10 (Pubitemid 35254059)
31. Dubey RK, Jackson EK (2009) Potential vascular actions of 2-methoxyestradiol. Trends Endocrinol Metab 20:374-379